Business Wire

Vistagen Receives New European Patent for AV-101

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, ...
JD Supra

Federal Circuit: Machine Learning Patents Fail Section 101 Patent Eligibility Challenge

The Federal Circuit's recent decision in Recentive Analytics, Inc. v. Fox Corp. (April 18, 2025) has garnered a lot of attention. This is not surprising: It hits on hot topics such as machine learning ...
Morningstar

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...
JD Supra

Interesting Recent § 101 Cases – Structural Components Are Not Enough

Joseph Drayton, Alan Teran Ph.D. Judge Choe-Groves of the United States Court of International Trade granted Defendant’s Motion to Dismiss and ruled Plaintiff’s asserted electronic storage room patent ...
The National Law Review

Another Diagnostic Patent Falls Under 101

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Managingip.com

Schizophrenia drug patent survives Section 101 test at Federal Circuit

In its important Vanda Pharmaceuticals v West-Ward Pharmaceuticals opinion, the Federal Circuit found the claims eligible at step two of the Mayo/Alice test whereas the district court found them ...
Business Wire

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, ...
Nasdaq

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

—European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis— —Further Extends Protections Afforded by CM-101 ...
Seeking Alpha

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today ...
Business Insider

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of ...
The National Law Review

Feel the Burn: Mechanical Improvement is Patent Eligible Under § 101

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Seeking Alpha

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected ...